Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.37 |
| ▸ | BRAF | P15056 | 7/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12912053 | 0.87 | NPC1 (0.39) | NPC1RAB9AMAPTBAZ2BNPY5R | |
| SCHEMBL12528518 | 0.83 | GAA (0.50) | NPC1RAB9AMAPTF10MEN1 | |
| SCHEMBL13757472 | 0.79 | NPC1 (0.64) | NPC1RAB9AMAPTBAZ2BBRAF | |
| SCHEMBL12912046 | 0.79 | PDE4B (0.38) | RAB9AF10MEN1KMT2AALDH1A1 | |
| SCHEMBL950506 | 0.77 | NPC1 (0.38) | NPC1RAB9AMAPTNPY5RF10 | |
| SCHEMBL12911681 | 0.76 | NPC1 (0.37) | NPC1RAB9AMAPTNPY5RF10 | |
| SCHEMBL13318559 | 0.74 | ALDH1A1 (0.37) | NPC1RAB9AMAPTNPY5RF10 | |
| SCHEMBL12912015 | 0.74 | F10 (0.39) | NPC1RAB9AMAPTF10MEN1 | |
| SCHEMBL20194448 | 0.74 | SMN1; SMN2 (0.42) | F10MEN1KMT2AALDH1A1 | |
| SCHEMBL1898437 | 0.74 | NPC1 (0.78) | NPC1RAB9AMAPTNPY5RMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968573-B2 | Hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20110071291-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | IKEGAMI HIROSHI | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071291-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | ACHE, H1-2, H1-0 | NPC1 2989/4885RAB9A 391/4885MAPT 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.